文献速递MDS 与骨髓增殖性肿瘤

骨髓增殖性肿瘤中衰弱的患病率及其与临床结局的关联:一项基于人群的研究

Prevalence of frailty and its association with clinical outcomes in myeloproliferative neoplasms: a population-based study.
PubMed 文献 · Blood Adv · 2023-01-01

该基于人群的研究纳入2004至2019年安大略癌症登记处10336例骨髓增殖性肿瘤(MPN)患者及1:4匹配对照,发现ET、PV、MF患者衰弱患病率显著高于匹配对照,且衰弱与更差的总生存独立相关。

要点

  • ET、PV、MF患者衰弱患病率显著高于匹配对照,标准化均数差分别为0.27、0.27、0.28。
  • 23%以上ET、20%PV、34%MF患者虽年龄<65岁或合并症极少,仍为衰弱或衰弱前期。
  • 校正年龄、性别和合并症后,衰弱仍独立关联更差总生存。

核心结论

  • MPN患者衰弱患病率显著高于匹配对照,且衰弱与更差总生存独立相关,与年龄或合并症无关。

研究设计与样本

  • 基于人群研究,纳入2004至2019年安大略癌症登记处所有新发MPN病例(N=10336;ET=5108;PV=3843;MF=1385)及按年龄、性别、居住地和收入1:4匹配的对照。

主要发现

  • ET、PV、MF患者衰弱患病率显著高于匹配对照,标准化均数差分别为0.27、0.27、0.28。
  • 23%以上ET、20%PV、34%MF患者虽年龄<65岁或合并症极少,仍为衰弱或衰弱前期。
  • 校正年龄、性别和合并症后,与mFI-fit患者相比,mFI-衰弱前期和mFI-衰弱患者总生存的风险比(95%CI)分别为:ET 1.6(1.3-1.9)和3.6(2.9-4.4),PV 1.3(1.1-1.5)和2.7(2.1-3.4),MF 1.2(1.0-1.5)和2.0(1.5-2.7)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical implications of frailty in myeloproliferative neoplasms (MPN), including essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), are unknown. In this population-based study, all incident cases of MPN from the Ontario cancer registry between 2004 and 2019 (N = 10 336; ET = 5108; PV = 3843; MF = 1385) and their matched controls (for age, sex, residence, and income) in a 1:4 ratio were included. Baseline frailty measured using the Johns Hopkins Adjusted Clinical Groups frailty indicator and McIsaac frailty index (mFI), categorized as fit, prefrail, or frail if mFI <0.10, 0.11 to 0.20, >0.20), was significantly higher in ET, PV, and MF compared with matched controls (standardized mean difference of 0.27, 0.27, and 0.28). Over 23%, 20%, and 34% of patients with ET, PV, and MF were frail or prefrail despite a younger age (<65 years) or minimal comorbidities. In Cox proportional regression, frailty was independently associated with worse overall survival (OS) after adjusting for age, sex, and comorbidities compared with mFI-fit patients. The hazard ratios (95% confidence interval) for OS for mFI-prefrail and mFI-frail patients were: 1.6 (1.3-1.9) and 3.6 (2.9-4.4) in ET, 1.3 (1.1-1.5) and 2.7 (2.1-3.4) in PV, and 1.2 (1.0-1.5) and 2.0 (1.5-2.7) in MF. Patients with MPN have a substantially higher prevalence of frailty compared with matched controls, which is associated with reduced OS, independent of age or comorbidities.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bankar A, Chan WC, Liu N, et al. Prevalence of frailty and its association with clinical outcomes in myeloproliferative neoplasms: a population-based study. Blood Adv. 2023. PMID: 37184988. doi:10.1182/bloodadvances.2023009825

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。